114 year-old cells converted to pluripotent stem cells

AgeX publishes evidence of supercentenarian cellular age reversal: new paper supports hypothesis of no upper age limit for reprogramming cellular aging. This is big news for Longevity research.

Supercentenarians, defined as people who have reached the age of 110, have long-confounded the scientific community due to the fact that they also typically live a life free of major age-related diseases until shortly before their death. New research [1] published today could lead to new insights into the fundamental mechanisms of aging and why supercentenarians not only live the longest, but also why they experience such extraordinary healthspans.

“We can essentially put their cells in a time machine and revert them to an earlier state …”


Longevity focused biotech firm AgeX Therapeutics (NYSE American: AGE), today announced the publication of a new paper in the peer-reviewed scientific journal “Biochemical and Biophysical Research Communications.”

The paper documents the work conducted by AgeX scientists, among others, who converted the cells of a deceased 114-year-old into young pluripotent stem cells, demonstrating first-time evidence of reversal of the telomere aging clock in a supercentenarian’s cells. The research introduces the possibility of identifying the underlying biology of extreme human lifespan and healthspan.

The donated cells were from “the longevity collection” a cell bank established by NIH’s National Institute on Aging.

“Clearly, we can learn a lot about aging and longevity from the longest of the long-lived, the supercentenarians, and we hope that this paper accelerates such research,” said the paper’s senior author, Dana Larocca, PhD, VP of Discovery Research at AgeX. “Now that we have converted the cells of one of the longest-lived people in history, a deceased 114-year-old American woman, to a young pluripotent state, researchers can do so with cells from other supercentenarians.”

“The goal is to understand specifically how these “extreme agers” manage to avoid the major chronic illnesses of aging better than any other age group including centenarians,” added Dr. Larocca. “We can essentially put their cells in a time machine and revert them to an earlier state, then study their biology to help unlock the mysteries of super-longevity. Scientists have long wondered, and now we know that we can indeed reset the developmental state and cellular age in the ‘oldest of the old.’”

Longevity Technology HEalthspan Lifespan
Healthspan and morbidity explainer: Super-centenarians have no major diseases through their longer life and experience compressed morbidity

By way of comparison the paper also describes undertaking a similar process with cells from two other donors: an eight-year-old with a rapid-aging syndrome commonly known as Progeria, and a 43-year-old, healthy disease-free control (HDC) subject. The paper notes that the supercentenarian’s cells reverted to induced pluripotent stem (iPS) cells at the same rate as the HDC subject and the Progeria patient. However, there may be some negative impact of extreme age on telomere resetting as this did not occur as frequently in the supercentenarian as in the other two donors.

This is very exciting news for research in the field of rejuvenation therapies and comes close behind other news from AgeX: the research collaboration with the University of California, Irvine using AgeX’s PureStem technology to derive neural stem cells; and a research collaboration with an as-yet-undisclosed Japanese biopharm company to further the development of its immunotolerance technology platform.

[1] https://www.sciencedirect.com/science/article/pii/S0006291X20303661?via%3Dihub
Image by analogicus from Pixabay 
Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

Global investment consortium slated to back Telocyte into Phase 1

Telomerase therapy ready for human Alzheimer’s trials. “There have been more than 400 registered trials for Alzheimer's and, by global consensus, every single one has...

Longevity 2020: shaping-up nicely

Over 45 confirmed speakers for this 5-day online event and a big thank you for your interest. We're moving fast! Longevity 2020 started just over...

Telomeres on repeat to inhibit inflamm-aging

Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres. Inflammation is a double-edged sword; while it is necessary...

Join me at my 100th birthday party in 2049!

We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years. One of the speakers at this month’s...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.